# A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy

> **NCT04995419** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma China, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Metastatic Urothelial Cancer

## Interventions

- **DRUG:** Enfortumab vedotin

## Key facts

- **NCT ID:** NCT04995419
- **Lead sponsor:** Astellas Pharma China, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-22
- **Primary completion:** 2022-05-13
- **Final completion:** 2025-08-27
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-10-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04995419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04995419, "A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04995419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*